Serviço de Imunologia, Complexo Hospitalar Universitário Prof. Edgard Santos, Universidade Federal da Bahia, Salvador, Bahia.
Curr Opin Infect Dis. 2012 Apr;25(2):141-4. doi: 10.1097/QCO.0b013e3283509cac.
Miltefosine is a new oral treatment against leishmaniasis. The evidence about its use in New and Old World cutaneous leishmaniasis is presented and discussed.
Miltefosine is being tested with small clinical trials mainly in endemic cutaneous leishmaniasis regions of South America and Iran. Severe cutaneous leishmaniasis forms successfully treated with miltefosine are reported.
The use of miltefosine in cutaneous leishmaniasis has been addressed in a few clinical trials. An important advantage of this drug is its oral administration when compared with the standard parenteral drugs in the context of a large-scale use in the inner regions of the endemic countries. Miltefosine also shows activity in severe or refractory cases. However, this review points out the need for further investment on clinical research into cutaneous leishmaniasis treatment.
米替福新是一种新的治疗利什曼病的口服药物。本文介绍并讨论了该药在新、旧大陆皮肤利什曼病中的应用。
米替福新主要在南美和伊朗的地方性皮肤利什曼病流行区进行小型临床试验。报告了成功用米替福新治疗的严重皮肤利什曼病病例。
在一些临床试验中已经研究了米替福新在皮肤利什曼病中的应用。与在流行国家的内部地区大规模使用时的标准的注射药物相比，该药的一个重要优势是其口服给药。米替福新在严重或难治性病例中也显示出活性。然而，本综述指出需要对皮肤利什曼病治疗的临床研究进行进一步投资。
